These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Increased measles-mumps-rubella (MMR) vaccine uptake in the context of a targeted immunisation campaign during a measles outbreak in a vaccine-reluctant community in England. Le Menach A, Boxall N, Amirthalingam G, Maddock L, Balasegaram S, Mindlin M. Vaccine; 2014 Feb 26; 32(10):1147-52. PubMed ID: 24440207 [Abstract] [Full Text] [Related]
7. Long-term immunogenicity of measles, mumps and rubella-containing vaccines in healthy young children: A 10-year follow-up. Carryn S, Feyssaguet M, Povey M, Di Paolo E. Vaccine; 2019 Aug 23; 37(36):5323-5331. PubMed ID: 31345639 [Abstract] [Full Text] [Related]
8. Age-stratified seroprevalence of measles, mumps and rubella (MMR) virus infections in Switzerland after the introduction of MMR mass vaccination. Matter L, Germann D, Bally F, Schopfer K. Eur J Epidemiol; 1997 Jan 23; 13(1):61-6. PubMed ID: 9062781 [Abstract] [Full Text] [Related]
13. Seroprevalence of measles, mumps and rubella among children in American Samoa, 2011, and progress towards West Pacific Region goals of elimination. Mahamud A, Masunu-Faleafaga Y, Walls L, Williams N, Garcia P, Teshale E, Williams R, Dulski T, Bellini WJ, Kutty PK. Vaccine; 2013 Aug 12; 31(36):3683-7. PubMed ID: 23770334 [Abstract] [Full Text] [Related]
18. Assessment of immune status against measles, mumps, and rubella in young Kuwaitis: MMR vaccine efficacy. Madi N, Altawalah H, Alfouzan W, Al-Nakib W, Al-Roumi E, Jeragh A. J Med Virol; 2020 Aug 12; 92(8):963-970. PubMed ID: 31919861 [Abstract] [Full Text] [Related]